Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of kidney cancer. Given the sustained response to ICIs in some patients after treatment discontinuation, intermittent dosing may minimize treatment toxicities and costs. Determining an optimal treatment strategy relies on personalized approaches.

Read the full article here

Related Articles